Bavarian Nordic's 1st-qtr loss narrows to $9.4M
Danish drugmaker Bavarian Nordic's first-quarter 2007 revenues totaled 28.8 million kroner ($5.2 million) versus 35.8 million kroner in the like, year-ago period, while the firm's loss before tax narrowed to 51.7 million kroner from 60.9 million kroner.
The company maintained its guidance for the full year, with revenues of around 130.0 million kroner and a loss before tax of 350.0 million kroner, as the US Government notified the firm of its intent to acquire 20 million doses of Imvamune smallpox vaccine.
As part of preparations for the delivery of smallpox vaccines for among others, the USA, BN has initiated commercial-scale production of the product at its Kvistgard facility in the first quarter of 2007. During this time, five batches were produced, including three validation lots.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze